Shares of Celldex Therapeutics, Inc. (CLDX) are rising more than 20 percent or $2.59 in Monday's morning trade at $15.39, after touching a new 52-week high of $15.65 earlier despite no specific news that could influence the stock.
U.S. stocks are rising on Monday, extending gains from the previous session, as investors shrugged off concerns about a surge in coronavirus cases and uncertainty about the U.S. presidential election.
Celldex is a biopharmaceutical company that focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics.
Celldex Therapeutics has traded in a range of $1.50 to $15.65 in the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.